ACELYRINSLRN
SLRN
About: Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
Employees: 130
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
450% more call options, than puts
Call options by funds: $22K | Put options by funds: $4K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
10% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 40
2% more funds holding
Funds holding: 122 [Q3] → 124 (+2) [Q4]
0.62% less ownership
Funds ownership: 88.26% [Q3] → 87.64% (-0.62%) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
36% less capital invested
Capital invested by funds: $434M [Q3] → $276M (-$158M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
12%
upside
Avg. target
$4.50
67%
upside
High target
$6
123%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Citigroup Samantha Semenkow 17% 1-year accuracy 2 / 12 met price target | 12%upside $3 | Neutral Maintained | 7 Jan 2025 |
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 28 / 157 met price target | 123%upside $6 | Neutral Maintained | 7 Jan 2025 |
Financial journalist opinion
Based on 4 articles about SLRN published over the past 30 days
Neutral
GlobeNewsWire
20 hours ago
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”).
Neutral
GlobeNewsWire
1 week ago
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC.
Neutral
GlobeNewsWire
1 week ago
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. (Nasdaq: ALMS).
Neutral
GlobeNewsWire
3 weeks ago
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN's development programs or intellectual property.
Neutral
Business Wire
1 month ago
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i.
Neutral
PRNewsWire
1 month ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisition of the company by Alumis Inc. (NASDAQ: ALMS).
Neutral
Business Wire
1 month ago
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock is fair to ACELYRIN shareholders. Halper Sadeh encourages ACELYRIN shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The.
Neutral
PRNewsWire
1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Acelyrin, Inc. (Nasdaq: SLRN ), relating to the proposed merger with Alumis Inc. Under the terms of the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock per share of common stock owned.
Neutral
Business Wire
1 month ago
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possible breaches of fiduciary duty and other violations of law in its transaction with Alumis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, ACELYRIN stockholders will receive only 0.4274 shares of Alumis common stock for each share of AC.
Neutral
GlobeNewsWire
1 month ago
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026
Charts implemented using Lightweight Charts™